Abstract
Human hepatitis B virus (HBV) causes chronic hepatitis disease which is a major public health problem worldwide. HBV has 4 genes encoding viral DNA polymerase, protein X and two structural proteins, the surface and core proteins. HBV DNA polymerase has been a primary target for the development of anti-HBV agents due to its enzymatic nature, and several nucleoside derivatives that inhibit HBV polymerase are currently used as anti-HBV therapeutics. On the other hand, accumulating information on the capsid assembly and the maturation process of HBV particles provides additional approaches for the development of anti-HBV agents. Proper interaction between core proteins is required for assembly of the nucleocapsid, and the specificity of the interactions between the capsid and surface proteins is essential for the maturation of active HBV in infected cells. In this article, the assembly process of active HBV particles and approaches to utilize the interactions of HBV structural proteins as target site for the development of anti-HBV agents are reviewed. In particular, novel approaches to target the assembly process and the interaction between HBV structural proteins are introduced.
Keywords: HBV, core protein, surface protein, capsid assembly, assembly inhibitor
Infectious Disorders - Drug Targets
Title: Interaction and Assembly of HBV Structural Proteins: Novel Target Sites of Anti-HBV Agents
Volume: 7 Issue: 3
Author(s): In-Geol Choi and Yeon Gyu Yu
Affiliation:
Keywords: HBV, core protein, surface protein, capsid assembly, assembly inhibitor
Abstract: Human hepatitis B virus (HBV) causes chronic hepatitis disease which is a major public health problem worldwide. HBV has 4 genes encoding viral DNA polymerase, protein X and two structural proteins, the surface and core proteins. HBV DNA polymerase has been a primary target for the development of anti-HBV agents due to its enzymatic nature, and several nucleoside derivatives that inhibit HBV polymerase are currently used as anti-HBV therapeutics. On the other hand, accumulating information on the capsid assembly and the maturation process of HBV particles provides additional approaches for the development of anti-HBV agents. Proper interaction between core proteins is required for assembly of the nucleocapsid, and the specificity of the interactions between the capsid and surface proteins is essential for the maturation of active HBV in infected cells. In this article, the assembly process of active HBV particles and approaches to utilize the interactions of HBV structural proteins as target site for the development of anti-HBV agents are reviewed. In particular, novel approaches to target the assembly process and the interaction between HBV structural proteins are introduced.
Export Options
About this article
Cite this article as:
Choi In-Geol and Yu Gyu Yeon, Interaction and Assembly of HBV Structural Proteins: Novel Target Sites of Anti-HBV Agents, Infectious Disorders - Drug Targets 2007; 7 (3) . https://dx.doi.org/10.2174/187152607782110077
DOI https://dx.doi.org/10.2174/187152607782110077 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Glimpse of Matrix Metalloproteinases in Diabetic Nephropathy
Current Medicinal Chemistry Carcinogenesis and Diabetic Wound Healing: Evidences of Parallelism
Current Diabetes Reviews Chronic Inflammation and Oxidative Stress as a Major Cause of Age- Related Diseases and Cancer
Recent Patents on Inflammation & Allergy Drug Discovery Adeno-associated Viral Vectors for Correction of Inborn Errors of Metabolism: Progressing Towards Clinical Application
Current Pharmaceutical Design TRP Channels and Cancer: New Targets for Diagnosis and Chemotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting Cancer Stem Cells with Natural Products
Current Drug Targets NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization
Current Pharmaceutical Design Past, Present and Future Therapeutics for Cerebellar Ataxias
Current Neuropharmacology Establishing Genomic/Transcriptomic Links Between Alzheimer’s Disease and Type 2 Diabetes Mellitus by Meta-Analysis Approach
CNS & Neurological Disorders - Drug Targets SALL4: Engine of Cell Stemness
Current Gene Therapy Selected Players in the Inflammation Cascade and Drugs That Target These Inflammation Genes Against Metastasis
Anti-Cancer Agents in Medicinal Chemistry Detection of Lysyl Oxidase-Like 2 (LOXL2), a Biomarker of Metastasis from Breast Cancers Using Human Blood Samples
Recent Patents on Biomarkers Micelle-based Systems for Pulmonary Drug Delivery and Targeting
Drug Delivery Letters From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications
Current Topics in Medicinal Chemistry HPV Pathway Profiling: HPV Related Cervical Dysplasia and Carcinoma Studies
Current Pharmaceutical Design Immunomics in Skin Cancer - Improvement in Diagnosis, Prognosis and Therapy Monitoring
Current Proteomics Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Current Drug Metabolism Cell-Penetrating Peptide-Mediated Therapeutic Molecule Delivery into the Central Nervous System
Current Neuropharmacology Purines and Pyrimidines: Metabolism, Function and Potential as Therapeutic Options in Neurodegenerative Diseases
Current Protein & Peptide Science Analytical Methods for Metallothionein Detection
Current Analytical Chemistry